{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:51:46Z","timestamp":1793400706223,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40265-025-02189-7","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T02:43:20Z","timestamp":1748573000000},"page":"1003-1012","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9859-6487","authenticated-orcid":false,"given":"Sebastiano","family":"Mercadante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"2189_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s002280050714","volume":"56","author":"F De Ponti","year":"2000","unstructured":"De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Euro J Clin Pharmacol. 2000;56:1\u201318.","journal-title":"Euro J Clin Pharmacol"},{"key":"2189_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/EDE.0b013e318225768b","volume":"22","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Post WS, Blasco-Colmenares E, et al. Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology. 2011;22:660\u201370.","journal-title":"Epidemiology"},{"key":"2189_CR3","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013\u201322.","journal-title":"N Engl J Med"},{"key":"2189_CR4","unstructured":"Anonymous. Points to consider: the assessment of the potential for QT interval prolongation by noncardiovascular medicinal products. European Agency for the Evaluation of Medicinal Products (EMEA); Committee for Proprietary Medicinal Products: CPMP\/986\/96"},{"key":"2189_CR5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/S0140-6736(05)73082-8","volume":"355","author":"JR Idle","year":"2000","unstructured":"Idle JR. The heart of psychotropic drug therapy. Lancet. 2000;355:1824.","journal-title":"Lancet"},{"key":"2189_CR6","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0885-3924(03)00313-0","volume":"26","author":"G Walker","year":"2003","unstructured":"Walker G, Wilcock A, Carey A, et al. Prolongation of the QT interval in palliative care patients. J Pain Symptom Manag. 2003;26:855\u20139.","journal-title":"J Pain Symptom Manag"},{"key":"2189_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/j.pain.0000000000002669","volume":"164","author":"S Mercadante","year":"2023","unstructured":"Mercadante S, Lo Cascio A, Adile C, Ferrera P, Casuccio A. Maddalena Opioid Switching Score in patients with cancer pain. Pain. 2023;164:91\u20137.","journal-title":"Pain"},{"key":"2189_CR8","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.jpainsymman.2017.10.017","volume":"55","author":"S Mercadante","year":"2018","unstructured":"Mercadante S, Bruera E. Methadone as a first-line opioid in cancer pain management: a systematic review. J Pain Symptom Manag. 2018;55:998\u20131003.","journal-title":"J Pain Symptom Manag"},{"key":"2189_CR9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-023-01876-7","volume":"83","author":"S Mercadante","year":"2023","unstructured":"Mercadante S. Intravenous methadone for perioperative and chronic cancer pain: a review of the literature. Drugs. 2023;83:865\u201371.","journal-title":"Drugs"},{"key":"2189_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jpain.2014.01.494","volume":"15","author":"R Chou","year":"2014","unstructured":"Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from American pain society and college on problems of drug dependence, in collaboration with the heart rhythm society. J Pain. 2014;15:321\u201337.","journal-title":"J Pain"},{"key":"2189_CR11","first-page":"493","volume":"61","author":"LJ Paulozzi","year":"2012","unstructured":"Paulozzi LJ. Vital signs: risk for overdose from methadone used for pain relief-United States, 1999 2010. MMWR. 2012;61:493\u20137.","journal-title":"MMWR"},{"key":"2189_CR12","first-page":"210","volume":"16","author":"CM Andrews","year":"2009","unstructured":"Andrews CM, Krantz MJ, Wedam EF, et al. Methadone-induced mortality in the treatment of chronic pain: role of QT prolongation. Cardiol J. 2009;16:210\u20137.","journal-title":"Cardiol J"},{"key":"2189_CR13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1592\/phco.23.6.802.32186","volume":"23","author":"MJ Krantz","year":"2003","unstructured":"Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy. 2003;23:802\u20135.","journal-title":"Pharmacotherapy"},{"key":"2189_CR14","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jpainsymman.2023.10.018","volume":"67","author":"V Pawate","year":"2024","unstructured":"Pawate V, Davila JSA, Reddy A. Routine monitoring of QTc interval as a barrier for efficient use of\u00a0methadone\u00a0in palliative care. J Pain Symptom Manag. 2024;67:e147\u201350.","journal-title":"J Pain Symptom Manag"},{"key":"2189_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jpainsymman.2004.06.012","volume":"29","author":"RA Cruciani","year":"2005","unstructured":"Cruciani RA, Sekine R, Homel P, et al. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manag. 2005;29:385\u201391.","journal-title":"J Pain Symptom Manag"},{"key":"2189_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jpainsymman.2006.02.010","volume":"32","author":"OM Fredheim","year":"2006","unstructured":"Fredheim OM, Borchgrevink PC, Hegrenaes L, et al. Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: a prospective 9-month follow-up study. J Pain Symptom Manag. 2006;32:180\u20135.","journal-title":"J Pain Symptom Manag"},{"key":"2189_CR17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4097\/kjae.2010.58.4.338","volume":"58","author":"B Huh","year":"2010","unstructured":"Huh B, Park CH. Retrospective analysis of low-dose methadone and QTc prolongation in chronic pain patients. Korean J Anesthesiol. 2010;58:338\u201343.","journal-title":"Korean J Anesthesiol"},{"key":"2189_CR18","first-page":"78","volume":"36","author":"JK McNamara","year":"2011","unstructured":"McNamara JK, Shinkazh N, Rim F, Sunga R, Cristian A. Methadone-associated prolongation of the QTc interval at doses used for chronic pain. P T. 2011;36:78\u2013107.","journal-title":"P T"},{"key":"2189_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.5055\/jom.2013.0167","volume":"9","author":"MHJ van der beuken-van Everdingen","year":"2013","unstructured":"van der beuken-van Everdingen MHJ, Geurts JW, Patijn J. Prolonged QT interval by methadone: relevance for daily practice? A prospective study in patients with cancer and noncancer pain. J Opioid Manag. 2013;9:263\u20137.","journal-title":"J Opioid Manag"},{"key":"2189_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jpainsymman.2013.09.021","volume":"48","author":"LC Price","year":"2014","unstructured":"Price LC, Wobeter B, Delate T, Kurz D, Shanahan RJ. Methadone\u00a0for\u00a0pain\u00a0and the risk of adverse cardiac outcomes. Pain Symptom Manag. 2014;48:333\u201342.","journal-title":"Pain Symptom Manag"},{"key":"2189_CR21","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/pme.12658","volume":"16","author":"S Grodofsky","year":"2015","unstructured":"Grodofsky S, Edson E, Huang S, et al. The QTc effect of low-dose methadone for chronic pain: a prospective pilot study. Pain Med. 2015;16:1112\u201321.","journal-title":"Pain Med"},{"key":"2189_CR22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0304-3959(03)00205-7","volume":"105","author":"CA Kornick","year":"2003","unstructured":"Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain. 2003;105:499\u2013506.","journal-title":"Pain"},{"key":"2189_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jpainsymman.2004.07.001","volume":"28","author":"S Reddy","year":"2004","unstructured":"Reddy S, Fisch M, Bruera E. Oral methadone for cancer pain: no indication of Q-T interval prolongation or torsades de pointes. J Pain Symptom Manag. 2004;28:301\u20132.","journal-title":"J Pain Symptom Manag"},{"key":"2189_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1089\/jpm.2009.0184","volume":"13","author":"S Reddy","year":"2010","unstructured":"Reddy S, Hui D, El Osta B, et al. The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med Palliat Med. 2010;13:33\u20138.","journal-title":"J Palliat Med Palliat Med."},{"key":"2189_CR25","first-page":"3421","volume":"21","author":"S Mercadante","year":"2013","unstructured":"Mercadante S, Prestia G, Adile C, Casuccio A. Changes of QTc interval after opioid switching to oral methadone. Support Care Cancer. 2013;21:3421\u20134.","journal-title":"Support Care Cancer"},{"key":"2189_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/1049909118811904","volume":"36","author":"AG Lovell","year":"2018","unstructured":"Lovell AG, McCrateProtus B, Saphire ML, et al. Evaluation of QTc interval prolongation among patients with cancer using enteral methadone. Am J Hosp Palliat Med. 2018;36:177\u201384.","journal-title":"Am J Hosp Palliat Med"},{"key":"2189_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40119-019-00156-4","volume":"9","author":"E Yamanaka","year":"2020","unstructured":"Yamanaka E, Chino S, Takasusuki T, Hamaguchi S, Yamaguchi S. Effect of methadone on cardiac repolarization in Japanese cancer patients: a longitudinal study. Cardiol Ther. 2020;9:119\u201326.","journal-title":"Cardiol Ther"},{"key":"2189_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/17581869.2025.2457316","volume":"15","author":"S Sheen","year":"2025","unstructured":"Sheen S, Choo J, Huh B, Chung M. The effect of oral methadone on the QTc interval in cancer pain patients. Pain Manag. 2025;15:21\u20135.","journal-title":"Pain Manag"},{"key":"2189_CR29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/10550887.2011.610710","volume":"30","author":"JA Martin","year":"2011","unstructured":"Martin JA, Campbell A, Killip T, et al. QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel. J Addict Dis. 2011;30:283\u2013330.","journal-title":"J Addict Dis"},{"key":"2189_CR30","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1089\/jpm.2016.0411","volume":"20","author":"KM Juba","year":"2017","unstructured":"Juba KM, Khadem TM, Hutchinson DJ, Brown JE. Methadone and corrected QT prolongation in pain and palliative care patients: a case-control study. J Palliat Med. 2017;20:722\u20138.","journal-title":"J Palliat Med"},{"key":"2189_CR31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.7326\/0003-4819-137-6-200209170-00010","volume":"137","author":"MJ Kranz","year":"2002","unstructured":"Kranz MJ, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137:501\u20134.","journal-title":"Ann Intern Med"},{"key":"2189_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000081416","volume":"11","author":"I Maremmani","year":"2005","unstructured":"Maremmani I, Pacini M, Cesaroni C, et al. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res. 2005;11:44\u20139.","journal-title":"Eur Addict Res"},{"key":"2189_CR33","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1592\/phco.2005.25.11.1523","volume":"25","author":"MJ Krantz","year":"2005","unstructured":"Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH. Effects of methadone on QT-interval dispersion. Pharmacotherapy. 2005;25:1523\u20139.","journal-title":"Pharmacotherapy"},{"key":"2189_CR34","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1472-8206.2010.00871.x","volume":"25","author":"A Perrin-Terrin","year":"2011","unstructured":"Perrin-Terrin A, Pathak A, Lapeyre-Mestre M. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France. Fundam Clin Pharmacol. 2011;25:503\u201310.","journal-title":"Fundam Clin Pharmacol"},{"key":"2189_CR35","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/pds.1112","volume":"14","author":"EC Pearson","year":"2005","unstructured":"Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2005;14:747\u201353.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2189_CR36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1517\/14740338.6.3.289","volume":"6","author":"GB Ehret","year":"2007","unstructured":"Ehret GB, Desmeules JA, Broers B. Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology. Expert Opin Drug Saf. 2007;6:289\u2013303.","journal-title":"Expert Opin Drug Saf"},{"key":"2189_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.7326\/0003-4819-150-6-200903170-00103","volume":"150","author":"MJ Krantz","year":"2009","unstructured":"Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc interval screening in methadone treatment. Ann Intern Med. 2009;150:387\u201395.","journal-title":"Ann Intern Med"},{"key":"2189_CR38","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jpainsymman.2019.05.021","volume":"58","author":"K Madden","year":"2019","unstructured":"Madden K, Jo E, Williams JL, Liu D, Bruera E. Corrected QT interval prolongation in pediatric and young adult patients on methadone for cancer-related pain. J Pain Symptom Manag. 2019;58:678\u201384.","journal-title":"J Pain Symptom Manag"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02189-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02189-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02189-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:20:22Z","timestamp":1757175622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02189-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2189"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02189-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"14 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SM does not have any conflict of interest that might be relevant to the contents of this manuscript.\u00a0Prof. Mercadante is an Editorial Board member of\n                      Drugs\n                      . He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent (participation & publication)"}},{"value":"Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Prof. Mercadante was the sole contributor to this article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s contributions"}}]}}